The Pharmasyntez Group of Companies carried out the first delivery of antineoplastic drugs to the Dominican Republic for the treatment of breast and prostate cancer. The drugs were registered in 2022 and manufactured at the Pharmasyntez-Nord site.

"Cooperation with the Dominican Republic began in 2019. At that moment, antineoplastic drugs were expensive enough in the country, and we had a clear opportunity to compete with regional importers. Antineoplastic drugs will now be easier for patients to get in the Dominican Republic thanks to the establishment of drug supply strategies. Pharmasyntez is the first supplier of Russian antineoplastic drugs to the Dominican Republic, thus we plan to occupy a worthy niche in this segment and continue long-term and effective cooperation with the region," Nikita Punia, Executive Director of the Pharmasyntez Group, told.

Pharmasyntez-Nord JSC (as a part of the Pharmasyntez Group) is a modern pharmaceutical research and production complex that specializes in the development and production of up-to-date and effective pharmaceuticals for the treatment of oncological diseases, autoimmune diseases, as well as endocrine system diseases. Currently, Pharmasyntez-Nord produces 45 trade names of antineoplastic drugs, 99% of which are included in the list of vital and essential drugs of the Ministry of Health of the Russian Federation.

The Pharmasyntez-Nord’s production capacity of antineoplastic drugs is 4 million syringes, 10 million vials of liquid and sterile forms, 2.5 million lyophilized products and 100 million tablets per year. To date, antineoplastic drugs created by the Pharmasyntez Group are exported to CIS countries.